{"filing":{"accession_number":"0001104659-26-092037","cik":"0001455365","ticker":"CGTX","company_name":"COGNITION THERAPEUTICS INC","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"tm2622462d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926092037/tm2622462d1_8k.htm"},"events":[{"id":25443,"run_id":23095,"accession_number":"0001104659-26-092037","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 6, 2026. The press release discloses financial results including R\u0026D expenses ($5.1M vs $11.5M YoY), G\u0026A expenses ($2.6M vs $2.5M YoY), net loss ($3.9M or $0.04 per share vs $6.7M or $0.11 per share YoY), and balance sheet data as of June 30, 2026. The filing includes unaudited selected financial data in tabular form and is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for earnings releases.","company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26275,"accession_number":"0001104659-26-092037","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 6, 2026. The press release discloses financial results including R\u0026D expenses ($5.1M vs $11.5M YoY), G\u0026A expenses ($2.6M vs $2.5M YoY), net loss ($3.9M or $0.04 per share vs $6.7M or $0.11 per share YoY), and balance sheet data as of June 30, 2026. The filing includes unaudited selected financial data in tabular form and is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:45:25.721376+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26275,"accession_number":"0001104659-26-092037","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 6, 2026. The press release discloses financial results including R\u0026D expenses ($5.1M vs $11.5M YoY), G\u0026A expenses ($2.6M vs $2.5M YoY), net loss ($3.9M or $0.04 per share vs $6.7M or $0.11 per share YoY), and balance sheet data as of June 30, 2026. The filing includes unaudited selected financial data in tabular form and is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:45:25.721376+00:00","company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","filing_date":"2026-08-06"}]}